<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685213</url>
  </required_header>
  <id_info>
    <org_study_id>H-47781-A</org_study_id>
    <nct_id>NCT04685213</nct_id>
  </id_info>
  <brief_title>Electrical Stimulation for Critically Ill Covid-19 Patients</brief_title>
  <acronym>Phase I</acronym>
  <official_title>Electrical Stimulation Therapy for Preventing Hospital-acquired Weakness in Critically Ill COVID-19 Patients - A Proof of Concept Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avazzia, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unfortunately, hospital-acquired weakness is highly prevalent among COVID-19 hospitalized&#xD;
      patients, who often require prolonged bed-rest or paralytics for an extended period of time&#xD;
      in order to maintain oxygenation. Prolonged bed rest has been associated with pronounced loss&#xD;
      of muscle mass that can exceed 10% over the 1st week, which leads to functional impairment&#xD;
      and complications post-hospital discharge. Physical therapy and in-hospital mobility program&#xD;
      may reduce the incident of hospital-acquired weakness, but they are often impractical for&#xD;
      COVID-19 patients. In particular, conventional mobility programs are challenging for those&#xD;
      who are being treated in an intensive Care Unit. The purpose of this study is to test&#xD;
      feasibility and proof-of-concept effectiveness of daily use of lower extremity electrical&#xD;
      stimulation (EE) therapy, as a practical solution to address lower extremity muscle&#xD;
      deconditioning, to address chronic consequences of COVID-19 including hospital-acquired&#xD;
      weakness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I:&#xD;
&#xD;
      The purpose of this study is to test feasibility and proof-of-concept effectiveness of lower&#xD;
      extremity electrical stimulation (EE) therapy to prevent muscular complications of COVID-19&#xD;
      including hospital-acquired weakness and neuropathy. This is a proof of concept randomized&#xD;
      control trial (RCT) study for prevention. Eligible participants (n=19 anticipated) will be&#xD;
      recruited from the Baylor St. Luke's' Medical Center (Houston, Texas). To be eligible&#xD;
      participants should be hospitalized because of COVID-19 infection and suspected to be at risk&#xD;
      for hospital acquired-weakness based on judgment of clinical intensivist investigators.&#xD;
      Participants will be excluded if they are paralyzed. Other exclusion criteria include blow&#xD;
      the knee amputation, those who have a demand-type cardiac pacemaker, implanted defibrillator&#xD;
      or other implanted electronic device; those with wound infection, and other conditions that&#xD;
      may interfere with outcomes or increase the risk of the use EE based on judgement of&#xD;
      clinicians.&#xD;
&#xD;
      The Investigators hypothesize that implementation of EE as means of regular activation of&#xD;
      lower extremity muscle is feasible and acceptable for the target population and would help to&#xD;
      retain lower extremity muscle mass, lower extremity tissue oxygen saturation and perfusion,&#xD;
      and thus reducing the severity of hospital acquired weakness and potentially improve outcomes&#xD;
      of treatment among COVID-19 patients.&#xD;
&#xD;
      Participants will be randomized to intervention (IG) or control group (CG)). The entire&#xD;
      cohort will receive daily EE in lower extremity (e.g. Gastronemius, tibial anterior muscle)&#xD;
      up to 1 hour. EE therapy will be provided using a bio-electric stimulation technology (BEST)&#xD;
      platform (Tennant Biomodulator PROÂ®, AVAZZIA, Inc.). The EE device will be functional for IG&#xD;
      and non-functional for CG. The primary outcomes include between group difference and change&#xD;
      from the baseline in muscle endurance, muscle strength, lower extremity tissue oxygen&#xD;
      saturation, neuropathy, and muscle atrophy. Outcomes will be assessed at baseline, time of&#xD;
      discharge or 2 weeks, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Actual">March 18, 2021</completion_date>
  <primary_completion_date type="Actual">March 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to intervention (IG) or control group (CG) with ratio of 1:1. The entire cohort will receive daily electrical stimulation (EE) in lower extremity (e.g. Gastronemius muscle) for up to 1 hour. The EE device will be functional for IG and non-functional for CG.&#xD;
Phase I will include patients (n=19) admitted to the hospital due to severe COVID-19 infection. The time frame for therapy will be 2 weeks or until hospital discharge, whichever comes first.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Devices may be active or sham.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation</measure>
    <time_frame>an average of 2 weeks (Phase I)</time_frame>
    <description>Gastrocnemius muscle endurance in response to 5 minutes of electrical stimulation therapy will be assessed with surface electromyography using a validated non-invasive device (Delsys Trino Wireless EMG System, MA, US).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ankle Strength</measure>
    <time_frame>an average of 2 weeks (Phase I)</time_frame>
    <description>Ankle strength will be measured in response to the average of three 5-second dorsiflexion maximum voluntary isometric contractions per 30 seconds of relaxation in-between using a dynamometer (RoMech Digital Hanging Scale).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Gastrocnemius Muscle Strength</measure>
    <time_frame>an average of 2 weeks (Phase I)</time_frame>
    <description>Gastrocnemius muscle strength will be measured by surface electromyography (Delsys Trino Wireless EMG System, MA, US) in response to the average of three 5-second dorsiflexion MVIC per 30 seconds of relaxation in-between.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Plantar Tissue Oxygen Saturation/Consumption</measure>
    <time_frame>an average of 2 weeks (Phase I)</time_frame>
    <description>Percentage of tissue oxygen saturation (SatO2) will be measured using a validated near-infrared (NIR) camera (Snapshot NIR, KENT Imaging Inc., Calgary, AB, Can) that detects an approximate value of real-time SatO2 level in superficial tissue. The metatarsus area including the five toes will be traced.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Covid19</condition>
  <condition>Muscle Atrophy</condition>
  <condition>Muscle Weakness</condition>
  <arm_group>
    <arm_group_label>Active E-Stim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham E-Stim</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrical Stimulation</intervention_name>
    <description>Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).</description>
    <arm_group_label>Active E-Stim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrical Stimulation - Sham</intervention_name>
    <description>Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).</description>
    <arm_group_label>sham E-Stim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COVID-19 test positive critically ill patients in need of assisted ventilation&#xD;
             requiring care in the intensive care unit&#xD;
&#xD;
          -  COVID-19 test positive critically ill patients in need of assisted ventilation&#xD;
             requiring prolonged care in the hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Paralyzed patients (i.e., rocuronium, cisatracurium) at the moment of enrollment&#xD;
&#xD;
          -  Patients under vasopressor therapy (i.e., norepinephrine, epinephrine, vasopressin) at&#xD;
             the moment of enrollment&#xD;
&#xD;
          -  Patients expected to be discharged in the next 24 hours&#xD;
&#xD;
          -  Patient has a demand-type cardiac pacemaker, implanted defibrillator or other&#xD;
             implanted electronic device.&#xD;
&#xD;
          -  Active wound infection&#xD;
&#xD;
          -  Below the knee amputations&#xD;
&#xD;
          -  Based on the clinicians decision whether the patient is eligible for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <results_first_submitted>October 12, 2021</results_first_submitted>
  <results_first_submitted_qc>January 12, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2022</results_first_posted>
  <last_update_submitted>January 18, 2022</last_update_submitted>
  <last_update_submitted_qc>January 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Bijan Najafi, PhD</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>electrical stimulation</keyword>
  <keyword>skin perfusion</keyword>
  <keyword>Muscle dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Asthenia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 21, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT04685213/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 21, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT04685213/SAP_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT04685213/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomized into intervention (n=9), and control (n=10) groups.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active E-Stim (Phase I)</title>
          <description>Subjects will receive an active electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sham E-Stim (Phase I)</title>
          <description>Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active E-Stim (Phase I)</title>
          <description>Subjects enrolled in Phase I will receive an active electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sham E-Stim (Phase I)</title>
          <description>Subjects enrolled in Phase I will receive a sham electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.9" spread="3.3"/>
                    <measurement group_id="B2" value="63.7" spread="2.9"/>
                    <measurement group_id="B3" value="65.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation</title>
        <description>Gastrocnemius muscle endurance in response to 5 minutes of electrical stimulation therapy will be assessed with surface electromyography using a validated non-invasive device (Delsys Trino Wireless EMG System, MA, US).</description>
        <time_frame>an average of 2 weeks (Phase I)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active E-Stim (Phase I)</title>
            <description>Subjects will receive an active electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham E-Stim (Phase I)</title>
            <description>Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation</title>
          <description>Gastrocnemius muscle endurance in response to 5 minutes of electrical stimulation therapy will be assessed with surface electromyography using a validated non-invasive device (Delsys Trino Wireless EMG System, MA, US).</description>
          <units>milliVolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.9" spread="0.65"/>
                    <measurement group_id="O2" value="322.7" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Ankle Strength</title>
        <description>Ankle strength will be measured in response to the average of three 5-second dorsiflexion maximum voluntary isometric contractions per 30 seconds of relaxation in-between using a dynamometer (RoMech Digital Hanging Scale).</description>
        <time_frame>an average of 2 weeks (Phase I)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active E-Stim (Phase I)</title>
            <description>Subjects will receive an active electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham E-Stim (Phase I)</title>
            <description>Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Strength</title>
          <description>Ankle strength will be measured in response to the average of three 5-second dorsiflexion maximum voluntary isometric contractions per 30 seconds of relaxation in-between using a dynamometer (RoMech Digital Hanging Scale).</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.4"/>
                    <measurement group_id="O2" value="2.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Gastrocnemius Muscle Strength</title>
        <description>Gastrocnemius muscle strength will be measured by surface electromyography (Delsys Trino Wireless EMG System, MA, US) in response to the average of three 5-second dorsiflexion MVIC per 30 seconds of relaxation in-between.</description>
        <time_frame>an average of 2 weeks (Phase I)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active E-Stim (Phase I)</title>
            <description>Subjects will receive an active electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham E-Stim (Phase I)</title>
            <description>Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gastrocnemius Muscle Strength</title>
          <description>Gastrocnemius muscle strength will be measured by surface electromyography (Delsys Trino Wireless EMG System, MA, US) in response to the average of three 5-second dorsiflexion MVIC per 30 seconds of relaxation in-between.</description>
          <units>milliVolts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.1"/>
                    <measurement group_id="O2" value="6.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plantar Tissue Oxygen Saturation/Consumption</title>
        <description>Percentage of tissue oxygen saturation (SatO2) will be measured using a validated near-infrared (NIR) camera (Snapshot NIR, KENT Imaging Inc., Calgary, AB, Can) that detects an approximate value of real-time SatO2 level in superficial tissue. The metatarsus area including the five toes will be traced.</description>
        <time_frame>an average of 2 weeks (Phase I)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active E-Stim (Phase I)</title>
            <description>Subjects will receive an active electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sham E-Stim (Phase I)</title>
            <description>Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for up to 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plantar Tissue Oxygen Saturation/Consumption</title>
          <description>Percentage of tissue oxygen saturation (SatO2) will be measured using a validated near-infrared (NIR) camera (Snapshot NIR, KENT Imaging Inc., Calgary, AB, Can) that detects an approximate value of real-time SatO2 level in superficial tissue. The metatarsus area including the five toes will be traced.</description>
          <units>Percentage of oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" spread="1.9"/>
                    <measurement group_id="O2" value="65.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>an average of 2 weeks(phase I)</time_frame>
      <desc>Serious adverse events related to electrical stimulation therapy (e.g. pain, muscle damage, skin irritation) will be collected during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active E-Stim (Phase I)</title>
          <description>During Phase I of the study, four electrode pads will be placed in the proximal and distal gastrocnemius muscle of each participant in order to receive electrical stimulation therapy for 1 hour during hospitalization for an average of 2 weeks. Adverse events related to electrical stimulation therapy (i.e., pain, muscle damage, skin irritation) will be collected.</description>
        </group>
        <group group_id="E2">
          <title>Sham E-Stim (Phase I)</title>
          <description>During Phase I of the study, four electrode pads will be placed in the proximal and distal gastrocnemius muscle of each participant in order to receive electrical stimulation therapy for 1 hour during hospitalization for an average of 2 weeks. Adverse events related to electrical stimulation therapy (i.e., pain, muscle damage, skin irritation) will be collected. However, the sham group will receive an inactive device. So, electrical stimulation will only be provided to quantify the study outcomes. Adverse events will also be reported during this time.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Bijan Najafi</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>7137987536</phone>
      <email>bijan.najafi@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

